Tineacide

Undecylenic Acid


Blaine Labs Inc.
Human Otc Drug
NDC 63347-500
Tineacide also known as Undecylenic Acid is a human otc drug labeled by 'Blaine Labs Inc.'. National Drug Code (NDC) number for Tineacide is 63347-500. This drug is available in dosage form of Cream. The names of the active, medicinal ingredients in Tineacide drug includes Undecylenic Acid - 10 g/100g . The currest status of Tineacide drug is Active.

Drug Information:

Drug NDC: 63347-500
The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
Proprietary Name: Tineacide
Also known as the trade name. It is the name of the product chosen by the labeler.
Product Type: Human Otc Drug
Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing.
Non Proprietary Name: Undecylenic Acid
Also known as the generic name, this is usually the active ingredient(s) of the product.
Labeler Name: Blaine Labs Inc.
Name of Company corresponding to the labeler code segment of the ProductNDC.
Dosage Form: Cream
The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources.
Status: Active
FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved.
Substance Name:UNDECYLENIC ACID - 10 g/100g
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.
Route Details:TOPICAL
The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Marketing Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Marketing Category: OTC MONOGRAPH FINAL
Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
Marketing Start Date: 01 Jan, 1995
This is the date that the labeler indicates was the start of its marketing of the drug product.
Marketing End Date: 16 Jan, 2025
This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached.
Application Number: part333C
This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.
Listing Expiration Date: 31 Dec, 2023
This is the date when the listing record will expire if not updated or certified by the firm.

OpenFDA Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Manufacturer Name:Blaine Labs Inc.
Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC.
RxCUI:830155
1250976
1250978
1250980
The RxNorm Concept Unique Identifier. RxCUI is a unique number that describes a semantic concept about the drug product, including its ingredients, strength, and dose forms.
Original Packager:Yes
Whether or not the drug has been repackaged for distribution.
UNII:K3D86KJ24N
Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information.

Packaging Information:

Package NDCDescriptionMarketing Start DateMarketing End DateSample Available
63347-500-0135.4 g in 1 BOTTLE (63347-500-01)01 Jan, 1995N/ANo
Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together.

Purpose:

Uses cures athlete's foot (tinea pedis) jock itch (tinea cruris) and ringworm (tinea corporis).

Product Elements:

Tineacide physician formula undecylenic acid undecylenic acid undecylenic acid water cetyl alcohol aloe vera leaf clotrimazole edetate disodium glyceryl monostearate hydroxyethyl cellulose (140 cps at 5%) english lavender oil methylparaben polyoxyl 100 stearate polysorbate 60 propylparaben stearic acid tea tree oil trolamine urea tineacide undecylenic acid undecylenic acid undecylenic acid water cetyl alcohol aloe vera leaf clotrimazole edetate disodium glyceryl monostearate hydroxyethyl cellulose (140 cps at 5%) english lavender oil methylparaben polyoxyl 100 stearate polysorbate 60 propylparaben stearic acid tea tree oil trolamine urea

Indications and Usage:

Uses for effective relief of itching, cracking, burning and discomfort which can accompany these conditions.

Warnings:

Warnings for external use only. avoid contact with eyes. if irritation occurs or if there is no improvement within 4 weeks (for athlete's foot or ringworm) or within 2 weeks (for jock itch) discontinue use and consult a physician. keep this and all drugs out of the reach of children. in case of accidental ingestion seek professional assistance or contact a poison control center immediately.

Dosage and Administration:

When using this product wash the affected area with soap and water and dry thoroughly. apply sparingly over affected area twice daily (morning and night) or as directed by a physician. for athlete's foot pay special attention to spaces between the toes. wear well-fitting ventilated shoes and change shoes and socks at least once daily. for athlete's foot and ringworm use daily for 4 weeks. for jock itch use daily for 2 weeks. if condition persists longer, consult a physician.

Package Label Principal Display Panel:

Tineacide label tineacide antifungal cream physician formula dispensed by a physician only. res blaine_tineacide_antifungal_cr blaine_tineacide_antifungal_phy_


Comments/ Reviews:

* Data of this site is collected from www.fda.gov. This page is for informational purposes only. Always consult your physician with any questions you may have regarding a medical condition.